Patient characteristics at treatment initiation
| Characteristics at treatment initiation . | peg-IFN . | HU . | P value . |
|---|---|---|---|
| n = 35 . | n = 86 . | ||
| Clinical data | |||
| Median age, y (range) | 60 (19-72) | 67 (23-90) | <.001 |
| Male sex, n (%) | 18 (51.4) | 31 (36) | .17 |
| History of thrombosis, n (%) | 8 (23) | 31 (36) | .23 |
| Type of thrombosis, arterial thrombosis, n (%) | 5 (14) | 17 (20) | .41 |
| Veinous thrombosis, n (%) | 3 (9) | 14 (16) | |
| Biology | |||
| Hemoglobin, g/dL, median (range) | 14.5 (11.9-17.2) | 14.5 (8.8-17.7) | .83 |
| Platelet count, × 109/L, median (range) | 665 (335-1772) | 729 (435-1963) | .63 |
| Leucocyte count, × 109/L, median (range) | 7.8 (3.4-12.8) | 8,3 (2.9-17.4) | .22 |
| r-IPSET | .05 | ||
| High risk, n (%) | 16 (46) | 56 (65) | |
| Intermediate risk, n (%) | 8 (23) | 20 (23) | |
| Low risk, n (%) | 4 (11) | 5 (6) | |
| Very low risk, n (%) | 7 (20) | 5 (6) | |
| ELN | .02 | ||
| High risk, n (%) | 24 (69) | 76 (88) | |
| Low risk, n (%) | 11 (31) | 10 (12) | |
| Driver mutation | .47 | ||
| JAK2 V617F, n (%) | 19 (54) | 51 (59) | |
| CALR, n (%) | 9 (26) | 17 (20) | |
| MPL, n (%) | 0 (0) | 5 (6) | |
| TN, n (%) | 7 (20) | 13 (15) | |
| Patients with additional mutations | |||
| None, n (%) | 21 (60) | 38 (44.2) | .17 |
| ≥2, n (%) | 6 (17.1) | 18 (20.9) | .82 |
| TET2, n (%) | 3 (8.6) | 16 (18.6) | .27 |
| DNMT3A, n (%) | 4 (11.4) | 9 (10.5) | 1 |
| ASXL1, n (%) | 2 (5.7) | 3 (3.5) | .63 |
| MPL (not W515), n (%) | 5 (14.3) | 3 (3.5) | .04 |
| Splicing, n (%) | 1 (2.9) | 7 (8.1) | .43 |
| Characteristics at treatment initiation . | peg-IFN . | HU . | P value . |
|---|---|---|---|
| n = 35 . | n = 86 . | ||
| Clinical data | |||
| Median age, y (range) | 60 (19-72) | 67 (23-90) | <.001 |
| Male sex, n (%) | 18 (51.4) | 31 (36) | .17 |
| History of thrombosis, n (%) | 8 (23) | 31 (36) | .23 |
| Type of thrombosis, arterial thrombosis, n (%) | 5 (14) | 17 (20) | .41 |
| Veinous thrombosis, n (%) | 3 (9) | 14 (16) | |
| Biology | |||
| Hemoglobin, g/dL, median (range) | 14.5 (11.9-17.2) | 14.5 (8.8-17.7) | .83 |
| Platelet count, × 109/L, median (range) | 665 (335-1772) | 729 (435-1963) | .63 |
| Leucocyte count, × 109/L, median (range) | 7.8 (3.4-12.8) | 8,3 (2.9-17.4) | .22 |
| r-IPSET | .05 | ||
| High risk, n (%) | 16 (46) | 56 (65) | |
| Intermediate risk, n (%) | 8 (23) | 20 (23) | |
| Low risk, n (%) | 4 (11) | 5 (6) | |
| Very low risk, n (%) | 7 (20) | 5 (6) | |
| ELN | .02 | ||
| High risk, n (%) | 24 (69) | 76 (88) | |
| Low risk, n (%) | 11 (31) | 10 (12) | |
| Driver mutation | .47 | ||
| JAK2 V617F, n (%) | 19 (54) | 51 (59) | |
| CALR, n (%) | 9 (26) | 17 (20) | |
| MPL, n (%) | 0 (0) | 5 (6) | |
| TN, n (%) | 7 (20) | 13 (15) | |
| Patients with additional mutations | |||
| None, n (%) | 21 (60) | 38 (44.2) | .17 |
| ≥2, n (%) | 6 (17.1) | 18 (20.9) | .82 |
| TET2, n (%) | 3 (8.6) | 16 (18.6) | .27 |
| DNMT3A, n (%) | 4 (11.4) | 9 (10.5) | 1 |
| ASXL1, n (%) | 2 (5.7) | 3 (3.5) | .63 |
| MPL (not W515), n (%) | 5 (14.3) | 3 (3.5) | .04 |
| Splicing, n (%) | 1 (2.9) | 7 (8.1) | .43 |
ELN, ≥60 years and/or history of thrombosis; high risk, (thrombosis history or age ≥60 years with JAK2 mutation); intermediate risk, (no thrombosis history, age ≥60 years, and JAK2-unmutated); LDH, lactate dehydrogenase; low risk, (no thrombosis history, age ≤60 years, and JAK2-mutated); r-IPSET, revised-IPSET; very low risk, (no thrombosis history, age ≤60 years, and JAK2-unmutated).